Showing 161 - 180 results of 223 for search '"Minneapolis"', query time: 0.06s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166
  7. 167
  8. 168

    Update on Surgical Techniques Best Practices to Optimize Outcomes Following Gel Stent Implantation by Vera V, Sheybani A, Panarelli JF, Grover DS, Lee J, Craven ER, Samuelson TW, Ahmed IIK

    Published 2025-01-01
    “…Vanessa Vera,1 Arsham Sheybani,2 Joseph F Panarelli,3 Davinder S Grover,4 James Lee,5 Earl Randy Craven,2 Thomas W Samuelson,6 Iqbal Ike K Ahmed7 1Allergan, an AbbVie company, Irvine, CA, USA; 2Washington University School of Medicine, St Louis, MO, USA; 3Department of Ophthalmology, New York University Langone Health, New York, NY, USA; 4Glaucoma Associates of Texas, Dallas, TX, USA; 5Colorado Eye Institute, Colorado Springs, CO, USA; 6Minnesota Eye Consultants, University of Minnesota, Minneapolis, MN, USA; 7John Moran Eye Center, University of Utah, Salt Lake City, UT, USACorrespondence: James Lee, Colorado Eye Institute, Colorado Springs, CO, 80924, USA, Email jlee@eyescolorado.comAbstract: The XEN® 45 Glaucoma Treatment System (gel stent; Allergan, an AbbVie company, Irvine, CA, USA) is a minimally invasive bleb-forming surgical device that was originally approved to lower intraocular pressure by diverting the aqueous humor from the anterior chamber to the subconjunctival space (like trabeculectomy) following ab-interno placement. …”
    Get full text
    Article
  9. 169
  10. 170
  11. 171
  12. 172
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180